Ascend Capital’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Ascend Capital’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-81,179	Closed	-$9.83M	–	203
2017 Q2	$9.83M	Buy	+81,179	New	+$9.4M	0.46%	75
2017 Q1	–	Sell	-42,375	Closed	-$4.6M	–	191
2016 Q4	$4.6M	Buy	+42,375	New	+$5.05M	0.23%	100

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Senvest Management New York $3.01B AUM 35.7% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Ascend Capital's ICPT Position: Q3 2017 in Review

Ascend Capital sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2017, closing a stake of 81,179 shares — an estimated $9.83M sold.

Ascend Capital first reported a position in ICPT in Q4 2016 and held it in 2 quarters. The position peaked at $9.83M in Q2 2017. 155 funds tracked by Wall St. Rank hold ICPT as of Q3 2017.

Ascend Capital reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Ascend Capital sold 81,179 Intercept Pharmaceuticals, Inc. shares in Q3 2017, an estimated $9.83M.
Ascend Capital first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2016 and held it in 2 quarters.
Ascend Capital's Intercept Pharmaceuticals, Inc. position peaked at $9.83M in Q2 2017.
155 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.